Literature DB >> 22302521

Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Baojian Wu1, Xiaoqiang Wang, Shuxing Zhang, Ming Hu.   

Abstract

PURPOSE: Catalytic selectivity of human UGT1A9, an important membrane-bound enzyme catalyzing glucuronidation of xenobiotics, was determined experimentally using 145 phenolics and analyzed by 3D-QSAR methods.
METHODS: Catalytic efficiency of UGT1A9 was determined by kinetic profiling. Quantitative structure activity relationships were analyzed using CoMFA and CoMSIA techniques. Molecular alignment of substrate structures was made by superimposing the glucuronidation site and its adjacent aromatic ring to achieve maximal steric overlap. For a substrate with multiple active glucuronidation sites, each site was considered a separate substrate.
RESULTS: 3D-QSAR analyses produced statistically reliable models with good predictive power (CoMFA: q2 = 0.548, r2 = 0.949, r pred 2 = 0.775; CoMSIA: q2 = 0.579, r2 = 0.876, r pred 2 = 0.700). Contour coefficient maps were applied to elucidate structural features among substrates that are responsible for selectivity differences. Contour coefficient maps were overlaid in the catalytic pocket of a homology model of UGT1A9, enabling identification of the UGT1A9 catalytic pocket with a high degree of confidence.
CONCLUSION: CoMFA/CoMSIA models can predict substrate selectivity and in vitro clearance of UGT1A9. Our findings also provide a possible molecular basis for understanding UGT1A9 functions and substrate selectivity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302521      PMCID: PMC3409642          DOI: 10.1007/s11095-012-0666-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

Review 1.  Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.

Authors:  Michael H Court
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

2.  A comparative molecular field analysis-based approach to prediction of sulfotransferase catalytic specificity.

Authors:  Vyas Sharma; Michael W Duffel
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

Review 3.  Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.

Authors:  Chie Emoto; Norie Murayama; Amin Rostami-Hodjegan; Hiroshi Yamazaki
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

Review 4.  Molecular modeling of cytochrome P450 and drug metabolism.

Authors:  Jing-Fang Wang; Kuo-Chen Chou
Journal:  Curr Drug Metab       Date:  2010-05       Impact factor: 3.731

5.  Ligand orientation governs conjugation capacity of UDP-glucuronosyltransferase 1A1.

Authors:  Yutaka Takaoka; Mika Ohta; Atsuko Takeuchi; Kenji Miura; Masafumi Matsuo; Toshiyuki Sakaeda; Aki Sugano; Hisahide Nishio
Journal:  J Biochem       Date:  2010-04-30       Impact factor: 3.387

6.  Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.

Authors:  Michael J Sorich; Paul A Smith; Ross A McKinnon; John O Miners
Journal:  Pharmacogenetics       Date:  2002-11

7.  Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme.

Authors:  Mika Kurkela; J Arturo García-Horsman; Leena Luukkanen; Saila Mörsky; Jyrki Taskinen; Marc Baumann; Risto Kostiainen; Jouni Hirvonen; Moshe Finel
Journal:  J Biol Chem       Date:  2002-11-14       Impact factor: 5.157

8.  In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9.

Authors:  Ryoichi Fujiwara; Miki Nakajima; Tetsunori Yamamoto; Hidemi Nagao; Tsuyoshi Yokoi
Journal:  Drug Metab Pharmacokinet       Date:  2009       Impact factor: 3.614

Review 9.  The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families.

Authors:  Anna Radominska-Pandya; Stacie M Bratton; Matthew R Redinbo; Michael J Miley
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

10.  The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.

Authors:  John O Miners; Peter I Mackenzie; Kathleen M Knights
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

View more
  6 in total

1.  Discovery of Hydroxyamidine Based Inhibitors of IDO1 for Cancer Immunotherapy with Reduced Potential for Glucuronidation.

Authors:  Christoph Steeneck; Olaf Kinzel; Simon Anderhub; Martin Hornberger; Sheena Pinto; Barbara Morschhaeuser; Floriane Braun; Gerald Kleymann; Thomas Hoffmann
Journal:  ACS Med Chem Lett       Date:  2020-01-27       Impact factor: 4.345

Review 2.  Understanding substrate selectivity of human UDP-glucuronosyltransferases through QSAR modeling and analysis of homologous enzymes.

Authors:  Dong Dong; Roland Ako; Ming Hu; Baojian Wu
Journal:  Xenobiotica       Date:  2012-03-02       Impact factor: 1.908

3.  Absolute quantification of UGT1A1 in various tissues and cell lines using isotope label-free UPLC-MS/MS method determines its turnover number and correlates with its glucuronidation activities.

Authors:  Beibei Xu; Song Gao; Baojian Wu; Taijun Yin; Ming Hu
Journal:  J Pharm Biomed Anal       Date:  2013-08-29       Impact factor: 3.935

4.  Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

Authors:  Michael J Osborne; Luciana Coutinho de Oliveira; Laurent Volpon; Hiba Ahmad Zahreddine; Katherine L B Borden
Journal:  J Mol Biol       Date:  2018-11-11       Impact factor: 5.469

5.  Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells.

Authors:  Yingjie Wei; Baojian Wu; Wen Jiang; Taijun Yin; Xiaobin Jia; Sumit Basu; Guangyi Yang; Ming Hu
Journal:  Mol Pharm       Date:  2013-04-23       Impact factor: 4.939

Review 6.  Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases.

Authors:  Ryoichi Fujiwara; Tsuyoshi Yokoi; Miki Nakajima
Journal:  Front Pharmacol       Date:  2016-10-24       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.